** Shares of therapy developer Prothena Corporation PRTA.O are down nearly 2% at $4.77 in pre-market trading
** Jefferies downgrades the stock's rating to "hold" from "buy"; slashes PT to $6 from $32, a 8.8% discount to the last close
** PRTA becomes stock with lowest PT, per Jefferies, on Wall Street
** We see uncertainty around the pipeline given the failure of the AL amyloidosis (a disease where abnormal proteins damage organs) drug - brokerage
** Adds it finds "risk" in the co's Alzheimer's drug PRX012 phase 1 trial data
** Co says phase 3 clinical trial of Birtamimab in patients with AL amyloidosis did not meet primary endpoint
** Avg rating of 10 analysts is "buy"; median PT $29.5— data compiled by LSEG
** PRTA falls ~52.49% YTD, up to last close
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。